# Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

> **NCT02447406** · PHASE1,PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 7 (actual)

## Conditions studied

- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** AZD6094
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT02447406
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-30
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-09-20
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447406, "Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02447406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*